New cocktail of drugs aims to boost stomach cancer treatment

NCT ID NCT07294664

Recruiting now Disease control Sponsor: The First Affiliated Hospital of Zhengzhou University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests whether adding an extra drug (either SHR2554 or apatinib) to standard immunotherapy plus chemotherapy can help people with advanced gastric cancer who don't get enough benefit from current treatments. About 78 adults with stage III or IV stomach cancer will receive the combination. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SHR1701 (an immunotherapy drug) combined with chemotherapy (CAPOX) and either SHR2554 (an EZH2 inhibitor) or apatinib (an anti-angiogenic drug)
What this could lead to: If successful, this could offer a more effective first-line treatment option for people with advanced gastric cancer who don't respond well to standard immunotherapy plus chemotherapy.
What could go wrong: This is an early Phase 2 trial with only 78 participants, so results may not apply to everyone. Adding more drugs also increases the risk of side effects, and the combination may not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED GASTRIC CANCER SHR1701

Contacts and locations

Locations

The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, 450000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.